This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Crist, W. M. Articles by Donaldson, S. S. Search for Related Content PubMed PubMed Citation Articles by Crist, W. M. Articles by Donaldson, S. S. Social Bookmarking                            What's this?

Intergroup Rhabdomyosarcoma Study-IV: Results for Patients With Nonmetastatic Disease

From the Intergroup Rhabdomyosarcoma Study Group (IRSG) representing the Children’s Cancer Group, the Pediatric Oncology Group, and the Intergroup Rhabdomyosarcoma Statistical Office, and the Quality Assurance Review Center, Arcadia, CA.

Address reprint requests to IRSG Operations Office, Children’s Oncology Group, 440 East Huntington Dr, #300, PO Box 60012, Arcadia, CA 91066-6012; email: jleeson{at}nccf.org

PURPOSE: The study goal was to improve outcome in children with rhabdomyosarcoma by comparing risk-based regimens of surgery, radiotherapy (RT) and chemotherapy.

PATIENTS AND METHODS: Eight hundred eighty-three previously untreated eligible patients with nonmetastatic rhabdomyosarcoma entered the Intergroup Rhabdomyosarcoma Study-IV (IRS-IV) (1991 to 1997) after surgery and were randomized treatment by primary tumor site, group (1 to 3), and stage (I to III). Failure-free survival (FFS) rates and survival were the end points used in comparisons between randomized groups and between patient subgroups treated on IRS-III and IRS-IV. Most patients were randomized to receive vincristine and dactinomycin (VA) and cyclophosphamide (VAC, n = 235), or VA and ifosfamide (VAI, n = 222), or vincristine, ifosfamide, and etoposide (VIE, n = 236). Patients with group 3 tumors were randomized to receive conventional RT (C-RT) versus hyperfractionated RT (HF-RT).

RESULTS: Overall 3-year FFS and survival were 77% and 86%, respectively. Three-year FFS rates with VAC, VAI, and VIE were 75%, 77%, and 77%, respectively (P = .42). No significant difference in outcome was noted with HF-RT versus C-RT (P = .85 and P = .90, respectively). Overall, patients with embryonal tumors benefited from intensive three-drug chemotherapy in IRS-IV (3-year FFS, 83%). The improvement was seen for patients with stage I or stage II/III, group 1/2 disease, many of whom received VA chemotherapy on IRS-III. Patients with stage 2/3, group 3 disease had similar outcomes on IRS-III and IRS-IV. Three-year FFS for the nonrandomized patient subsets was 75% with renal abnormalities; 81% for paratesticular, group 1 cases; and 91% for group 1/2 orbit or eyelid tumors. Patients with paratesticular primaries had poorer outcomes if they were more than 10 years old (3-year FFS, 63% v 90%). Myelosuppression occurred in most patients, but toxic deaths occurred in less than 1%.

CONCLUSION: VAC and VAI or VIE with surgery (with or without RT), are equally effective for patients with local or regional rhabdomyosarcoma and are more effective for embryonal tumors than therapies used previously. Younger patients with group 1 paratesticular embryonal tumors and all patients with group 1/2 orbit or eyelid tumors can usually be cured with VA chemotherapy along with postoperative RT for group 2 disease.

See Appendix for additional members of the Intergroup Rhabdomyosarcoma Study Group.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				O. Oberlin, O. Fawaz, A. Rey, P. Niaudet, V. Ridola, D. Orbach, C. Bergeron, A. S. Defachelles, J.-C. Gentet, C. Schmitt, et al. Long-Term Evaluation of Ifosfamide-Related Nephrotoxicity in Children J. Clin. Oncol., November 10, 2009; 27(32): 5350 - 5355. [Abstract] [Full Text] [PDF]

				C. A.S. Arndt, J. A. Stoner, D. S. Hawkins, D. A. Rodeberg, A. A. Hayes-Jordan, C. N. Paidas, D. M. Parham, L. A. Teot, M. D. Wharam, J. C. Breneman, et al. Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803 J. Clin. Oncol., November 1, 2009; 27(31): 5182 - 5188. [Abstract] [Full Text] [PDF]

				D. A. Rodeberg, J. A. Stoner, A. Hayes-Jordan, S. C. Kao, S. L. Wolden, S. J. Qualman, W. H. Meyer, and D. S. Hawkins Prognostic Significance of Tumor Response at the End of Therapy in Group III Rhabdomyosarcoma: A Report From the Children's Oncology Group J. Clin. Oncol., August 1, 2009; 27(22): 3705 - 3711. [Abstract] [Full Text] [PDF]

				T. M. Dantonello, C. Int-Veen, D. Harms, I. Leuschner, B. F. Schmidt, M. Herbst, H. Juergens, H.-G. Scheel-Walter, S. S. Bielack, T. Klingebiel, et al. Cooperative Trial CWS-91 for Localized Soft Tissue Sarcoma in Children, Adolescents, and Young Adults J. Clin. Oncol., March 20, 2009; 27(9): 1446 - 1455. [Abstract] [Full Text] [PDF]

				A.-S. Defachelles, A. Rey, O. Oberlin, D. Spooner, and M. C.G. Stevens Treatment of Nonmetastatic Cranial Parameningeal Rhabdomyosarcoma in Children Younger Than 3 Years Old: Results From International Society of Pediatric Oncology Studies MMT 89 and 95 J. Clin. Oncol., March 10, 2009; 27(8): 1310 - 1315. [Abstract] [Full Text] [PDF]

				E. Davicioni, M. J. Anderson, F. G. Finckenstein, J. C. Lynch, S. J. Qualman, H. Shimada, D. E. Schofield, J. D. Buckley, W. H. Meyer, P. H.B. Sorensen, et al. Molecular Classification of Rhabdomyosarcoma--Genotypic and Phenotypic Determinants of Diagnosis: A Report from the Children's Oncology Group Am. J. Pathol., February 1, 2009; 174(2): 550 - 564. [Abstract] [Full Text] [PDF]

				A. Ferrari, R. Miceli, C. Meazza, E. Zaffignani, A. Gronchi, L. Piva, P. Collini, M. Podda, M. Massimino, R. Luksch, et al. Soft Tissue Sarcomas of Childhood and Adolescence: The Prognostic Role of Tumor Size in Relation to Patient Body Size J. Clin. Oncol., January 20, 2009; 27(3): 371 - 376. [Abstract] [Full Text] [PDF]

				Pathology Quiz Case 2: Diagnosis Arch Otolaryngol Head Neck Surg, October 1, 2008; 134(10): 1118 - 1119. [Full Text] [PDF]

				H. W Tuffaha, I. M Treish, and L. Zaru The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting Journal of Oncology Pharmacy Practice, September 1, 2008; 14(3): 131 - 138. [Abstract] [PDF]

				Y.-X. Ren, F. G. Finckenstein, D. A. Abdueva, V. Shahbazian, B. Chung, K. I. Weinberg, T. J. Triche, H. Shimada, and M. J. Anderson Mouse Mesenchymal Stem Cells Expressing PAX-FKHR Form Alveolar Rhabdomyosarcomas by Cooperating with Secondary Mutations Cancer Res., August 15, 2008; 68(16): 6587 - 6597. [Abstract] [Full Text] [PDF]

				F. G. Barr and W. H. Meyer Rhabdomyosarcoma: An Overview of Biology, Clinical Features, and the Current Children's Oncology Group Studies ASCO Educational Book, January 1, 2008; 2008(1): 465 - 470. [Abstract] [Full Text] [PDF]

				M. Burke, J. R. Anderson, S. C. Kao, D. Rodeberg, S. J. Qualman, S. L. Wolden, W. H. Meyer, and P. P. Breitfeld Assessment of Response to Induction Therapy and Its Influence on 5-Year Failure-Free Survival in Group III Rhabdomyosarcoma: The Intergroup Rhabdomyosarcoma Study-IV Experience A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group J. Clin. Oncol., November 1, 2007; 25(31): 4909 - 4913. [Abstract] [Full Text] [PDF]

				K. M. Skubitz and D. R. D'Adamo Sarcoma Mayo Clin. Proc., November 1, 2007; 82(11): 1409 - 1432. [Abstract] [Full Text] [PDF]

				E. M. Chung, J. G. Smirniotopoulos, C. S. Specht, J. W. Schroeder, and R. Cube From the Archives of the AFIP: Pediatric Orbit Tumors and Tumorlike Lesions: Nonosseous Lesions of the Extraocular Orbit RadioGraphics, November 1, 2007; 27(6): 1777 - 1799. [Abstract] [Full Text] [PDF]

				E. F. Petricoin III, V. Espina, R. P. Araujo, B. Midura, C. Yeung, X. Wan, G. S. Eichler, D. J. Johann Jr., S. Qualman, M. Tsokos, et al. Phosphoprotein Pathway Mapping: Akt/Mammalian Target of Rapamycin Activation Is Negatively Associated with Childhood Rhabdomyosarcoma Survival Cancer Res., April 1, 2007; 67(7): 3431 - 3440. [Abstract] [Full Text] [PDF]

				A. S. Pappo, E. Lyden, P. Breitfeld, S. S. Donaldson, E. Wiener, D. Parham, K. R. Crews, P. Houghton, and W. H. Meyer Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With Vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group J. Clin. Oncol., February 1, 2007; 25(4): 362 - 369. [Abstract] [Full Text] [PDF]

				J. L. Meza, J. Anderson, A. S. Pappo, and W. H. Meyer Analysis of Prognostic Factors in Patients With Nonmetastatic Rhabdomyosarcoma Treated on Intergroup Rhabdomyosarcoma Studies III and IV: The Children's Oncology Group J. Clin. Oncol., August 20, 2006; 24(24): 3844 - 3851. [Abstract] [Full Text] [PDF]

				J. J. Lager, E. R. Lyden, J. R. Anderson, A. S. Pappo, W. H. Meyer, and P. P. Breitfeld Pooled Analysis of Phase II Window Studies in Children With Contemporary High-Risk Metastatic Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group J. Clin. Oncol., July 20, 2006; 24(21): 3415 - 3422. [Abstract] [Full Text] [PDF]

				D. P. Lee, J. M. Skolnik, and P. C. Adamson Pediatric Phase I Trials in Oncology: An Analysis of Study Conduct Efficiency J. Clin. Oncol., November 20, 2005; 23(33): 8431 - 8441. [Abstract] [Full Text] [PDF]

				S. L. Spunt, T. A. Sweeney, M. M. Hudson, C. A. Billups, M. J. Krasin, and A. L. Hester Late Effects of Pelvic Rhabdomyosarcoma and Its Treatment in Female Survivors J. Clin. Oncol., October 1, 2005; 23(28): 7143 - 7151. [Abstract] [Full Text] [PDF]

				P. P. Breitfeld and W. H. Meyer Rhabdomyosarcoma: New Windows of Opportunity Oncologist, August 1, 2005; 10(7): 518 - 527. [Abstract] [Full Text] [PDF]

				D. Orbach, A. Rey, O. Oberlin, J. S. de Toledo, M.J. Terrier-Lacombe, A. van Unnik, E. Quintana, and M.C.G. Stevens Soft Tissue Sarcoma or Malignant Mesenchymal Tumors in the First Year of Life: Experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee J. Clin. Oncol., July 1, 2005; 23(19): 4363 - 4371. [Abstract] [Full Text] [PDF]

				S. S. Donaldson and J. R. Anderson Rhabdomyosarcoma: Many Similarities, a Few Philosophical Differences J. Clin. Oncol., April 20, 2005; 23(12): 2586 - 2587. [Full Text] [PDF]

				M. C.G. Stevens, A. Rey, N. Bouvet, C. Ellershaw, F. Flamant, J. L. Habrand, H. B. Marsden, H. Martelli, J. S. de Toledo, R. D Spicer, et al. Treatment of Nonmetastatic Rhabdomyosarcoma in Childhood and Adolescence: Third Study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89 J. Clin. Oncol., April 20, 2005; 23(12): 2618 - 2628. [Abstract] [Full Text] [PDF]

				D. Williamson, Y.-J. Lu, T. Gordon, R. Sciot, A. Kelsey, C. Fisher, C. Poremba, J. Anderson, K. Pritchard-Jones, and J. Shipley Relationship Between MYCN Copy Number and Expression in Rhabdomyosarcomas and Correlation With Adverse Prognosis in the Alveolar Subtype J. Clin. Oncol., February 1, 2005; 23(4): 880 - 888. [Abstract] [Full Text] [PDF]

				C. Arndt, D. Hawkins, J.R. Anderson, P. Breitfeld, R. Womer, and W. Meyer Age Is a Risk Factor for Chemotherapy-Induced Hepatopathy With Vincristine, Dactinomycin, and Cyclophosphamide J. Clin. Oncol., May 15, 2004; 22(10): 1894 - 1901. [Abstract] [Full Text] [PDF]

				M. D. Wharam, J. Meza, J. Anderson, J. C. Breneman, S. S. Donaldson, T. J. Fitzgerald, J. Michalski, L. A. Teot, E. S. Wiener, and W. H. Meyer Failure Pattern and Factors Predictive of Local Failure in Rhabdomyosarcoma: A Report of Group III Patients on the Third Intergroup Rhabdomyosarcoma Study J. Clin. Oncol., May 15, 2004; 22(10): 1902 - 1908. [Abstract] [Full Text] [PDF]

				K. C. Harris, S. F. Conley, and J. E. Kerschner Foreign Body Granuloma of the External Auditory Canal Pediatrics, April 1, 2004; 113(4): e371 - e373. [Abstract] [Full Text] [PDF]

				A. M. Friedmann, N. J. Tarbell, P. W. Schaefer, and B. L. Hoch Case 4-2004 - A Nine-Month-Old Boy with an Orbital Rhabdomyosarcoma N. Engl. J. Med., January 29, 2004; 350(5): 494 - 502. [Full Text] [PDF]

				A. Schuck, A. C. Mattke, B. Schmidt, D. S. Kunz, D. Harms, R. Knietig, J. Treuner, and E. Koscielniak Group II Rhabdomyosarcoma and Rhabdomyosarcomalike Tumors: Is Radiotherapy Necessary? J. Clin. Oncol., January 1, 2004; 22(1): 143 - 149. [Abstract] [Full Text] [PDF]

				K. Aflatoon, A. J. Aboulafia, E. F. McCarthy Jr, F. J. Frassica, and A. M. Levine Pediatric Soft-Tissue Tumors J. Am. Acad. Ortho. Surg., September 1, 2003; 11(5): 332 - 343. [Abstract] [Full Text] [PDF]

				C.-C. Chang and V. B. Shidham Molecular Genetics of Pediatric Soft Tissue Tumors: Clinical Application J. Mol. Diagn., August 1, 2003; 5(3): 143 - 154. [Abstract] [Full Text] [PDF]

				B. J. Weigel, D. A. Rodeberg, A. M. Krieg, and B. R. Blazar CpG Oligodeoxynucleotides Potentiate the Antitumor Effects of Chemotherapy or Tumor Resection in an Orthotopic Murine Model of Rhabdomyosarcoma Clin. Cancer Res., August 1, 2003; 9(8): 3105 - 3114. [Abstract] [Full Text] [PDF]

				H P McDowell Update on childhood rhabdomyosarcoma Arch. Dis. Child., April 1, 2003; 88(4): 354 - 357. [Abstract] [Full Text] [PDF]

				R. J. Stewart, H. Martelli, O. Oberlin, A. Rey, N. Bouvet, R. D. Spicer, J. Godzinski, and M. C.G. Stevens Treatment of Children With Nonmetastatic Paratesticular Rhabdomyosarcoma: Results of the Malignant Mesenchymal Tumors Studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology J. Clin. Oncol., March 1, 2003; 21(5): 793 - 798. [Abstract] [Full Text] [PDF]

				J. C. Breneman, E. Lyden, A. S. Pappo, M. P. Link, J. R. Anderson, D. M. Parham, S. J. Qualman, M. D. Wharam, S. S. Donaldson, H. M. Maurer, et al. Prognostic Factors and Clinical Outcomes in Children and Adolescents With Metastatic Rhabdomyosarcoma--A Report From the Intergroup Rhabdomyosarcoma Study IV J. Clin. Oncol., January 1, 2003; 21(1): 78 - 84. [Abstract] [Full Text] [PDF]

				K. S. Baker, J. R. Anderson, T. E. Lobe, M. D. Wharam, S. J. Qualman, R. B. Raney, F. B. Ruymann, R. B. Womer, W. H. Meyer, M. P. Link, et al. Children From Ethnic Minorities Have Benefited Equally as Other Children From Contemporary Therapy for Rhabdomyosarcoma: A Report From the Intergroup Rhabdomyosarcoma Study Group J. Clin. Oncol., November 15, 2002; 20(22): 4428 - 4433. [Abstract] [Full Text] [PDF]

				P. H.B. Sorensen, J. C. Lynch, S. J. Qualman, R. Tirabosco, J. F. Lim, H. M. Maurer, J. A. Bridge, W. M. Crist, T. J. Triche, and F. G. Barr PAX3-FKHR and PAX7-FKHR Gene Fusions Are Prognostic Indicators in Alveolar Rhabdomyosarcoma: A Report From the Children's Oncology Group J. Clin. Oncol., June 1, 2002; 20(11): 2672 - 2679. [Abstract] [Full Text] [PDF]

				L. M. Smith, J. R. Anderson, S. J. Qualman, W. M. Crist, C. N. Paidas, L. A. Teot, A. S. Pappo, M. P. Link, H. E. Grier, E. S. Wiener, et al. Which Patients With Microscopic Disease and Rhabdomyosarcoma Experience Relapse After Therapy? A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group J. Clin. Oncol., October 15, 2001; 19(20): 4058 - 4064. [Abstract] [Full Text] [PDF]